Opus Genetics, Inc. (NASDAQ:IRD) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of series B Non-Voting Convertible Preferred Stock Announced: US$25M · US$3.39 a share Buyers: Adage Capital Management; Trails Edge Capital Partners; Marshall Wace Use of proceeds: Advance gene therapy clinical programs, working capital and general corporate purposes | Feb 13, 2026 |
| Registered direct offering of equity securities Closed: US$23M raised · US$2.09 a share Buyers: Perceptive Advisors (led the financing); Balyasny Asset Management (led the financing); Nantahala Capital (participated) Use of proceeds: Advance LCA5 and BEST-1 gene therapy clinical programs, working capital and general corporate purposes | Nov 12, 2025 |
| Public offering of shares of common stock, or common stock equivalents, and warrants Closed: US$20M raised · US$0.95 a share · Warrants at US$0.95 for 60 months · Craig-Hallum Dealers: Craig-Hallum (lead) Buyers: Perceptive Advisors; Nantahala Capital Use of proceeds: Extending cash runway and funding key upcoming milestones for the gene therapy portfolio | Mar 31, 2025 |
| Private placement of shares of common stock and warrants Closed: US$1.5M raised · US$1.275 a share · Warrants at US$1.15 for 60 months Buyers: George Magrath; Cam Gallagher Insiders: CEO George Magrath and board chairman Cam Gallagher participated Use of proceeds: Clinical development of OPGx-LCA5 and OPGx-BEST1 gene therapy programs, general corporate purposes and working capital | Mar 31, 2025 |